Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity

BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Res Ther
Asıl Yazarlar: Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553803/
https://ncbi.nlm.nih.gov/pubmed/28800777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1397-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller